Biotech & Pharma: Hong Kong IPO applicants (103 companies)
103 Biotech & Pharma companies that have filed to list in Hong Kong, newest first, with what each does and links to its filings.
- 2026-09-30
Application ProofACROBIOSYSTEMS CO., LTD北京百普赛斯生物科技股份有限公司Develops, produces and sells biological reagents—recombinant proteins, antibodies and analytical assay kits—plus technical services supporting biopharmaceutical R&D in China and globally. Per Frost & Sullivan, ranked third globally in recombinant proteins with a 2.7% revenue share in 2025.
- 2026-09-18
Application ProofZhejiang Jingxin Pharmaceutical Co., Ltd.浙江京新药业股份有限公司Pharmaceutical group in China developing and selling drugs focused on CNS disorders and cardiovascular/cerebrovascular diseases, including generics, the innovative drug Dimdazenil, TCM, biologics, APIs, and medical equipment. 2025 revenue was RMB4,069.4 million with net profit of RMB771.7 million.
- 2026-09-03
Application ProofSHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.深圳信立泰药业股份有限公司Develops, produces, and sells pharmaceuticals and medical devices focused on cardiovascular-kidney-metabolic diseases in China, including innovative drugs, generics, and biosimilars. Ranked second in in-hospital sales of cardiovascular drugs in China in 2025 with an 11.3% market share, per Frost & Sullivan.
- 2026-08-31
Application ProofProteLight Pharmaceuticals (Jiangsu) Co., Ltd.普莱医药（江苏）股份有限公司Develops antimicrobial peptide therapeutics focusing on anti-infectives and metabolic diseases. Core product PL-5 (Peceleganan) is a topical spray treating secondary infections of burn wounds and diabetic foot infections. Operates in China.
- 2026-08-30
Application ProofHangzhou Bangshun Pharmaceutical Co., Ltd.杭州邦顺制药股份有限公司Develops and commercializes oral small-molecule drugs for oncology and autoimmune diseases, with a pipeline including NMPA-approved bezacitinib, a JAK inhibitor for myelofibrosis, and one registrational candidate, operating in China.
- 2026-08-28
Application ProofDevelops gene therapies and oligonucleotide therapeutics for neurological and ophthalmic diseases, with a nine-candidate pipeline including treatments for wet AMD and SMA Type 1 in clinical trials in China and the United States.
- 2026-08-28
Application ProofBetta Pharmaceuticals Co., Ltd.贝达药业股份有限公司Fully integrated commercial-stage biopharmaceutical company in China developing and commercializing innovative oncology drugs, with nine marketed products including targeted lung cancer therapies (icotinib, ensartinib, vorolanib) and a pipeline of over ten clinical programs.
- 2026-08-28
Application ProofClinical-stage gene therapy company developing in-house recombinant adeno-associated virus (rAAV) gene therapies targeting ophthalmic and cardiovascular diseases, with a pipeline of six candidates including treatments for X-linked retinitis pigmentosa, nAMD, DME, and inherited retinal diseases in China.
- 2026-08-28
Application ProofVivaVision Biotech (Zhejiang) Co., Ltd.维眸生物科技(浙江)股份有限公司Develops small-molecule ophthalmic drugs targeting ocular surface and posterior segment diseases, with R&D centers and subsidiaries in China and overseas, and plans to commercialize product candidates in domestic and international markets.
- 2026-08-27
Application ProofDIZAL PHARMACEUTICAL CO., LTD.迪哲(江苏)医药股份有限公司Develops and commercializes oncology and hematology drugs in Chinese Mainland, including ZEGFROVY, an EGFR TKI for lung cancer, and golidocitinib, a JAK1 inhibitor, with additional clinical-stage drug candidates.
- 2026-08-26
Application ProofZenshine Pharmaceuticals (Nanjing) Group Co., Ltd.征祥医药（南京）集团股份有限公司Commercial-stage biopharmaceutical company developing small-molecule therapeutics for viral infectious diseases, oncology, and inflammatory disorders in China. Its core product, sebaloxavir marboxil, an influenza PA endonuclease inhibitor, was approved by the NMPA in 2025 for treating influenza in adults and adolescents.
- 2026-08-21
Application ProofTyligand Bioscience Ltd.泰励生物有限公司Clinical-stage biopharmaceutical company discovering and developing cancer therapeutics, including small molecules and ADCs. Core product TSN1611, an oral KRAS G12D inhibitor, is in phase 2 trials in the US and China for non-small cell lung cancer treatment.
- 2026-08-21
Application ProofInventisBio Co., Limited益方生物科技（上海）股份有限公司Develops small-molecule drugs for oncology, autoimmune and metabolic diseases, with a pipeline of eight candidates including TYK2 inhibitor D-2570 and SERD taragarestrant (D-0502), both in Phase III trials in China; A shares listed on the STAR Market.
- 2026-08-20
Application ProofPANACRO (Hangzhou) Pharmaceutical Consulting Co., Ltd.博纳西亚(杭州)医药科技股份有限公司Hangzhou-based clinical CRO providing clinical trial technical services on a contract basis to pharmaceutical and biotechnology companies in China and internationally, supported by proprietary digital systems such as CTMS, eTMF and CTFS. Ranked 14th in China-headquartered clinical CRO revenue in 2025 with 0.7% market share (per the prospectus).
- 2026-08-18
Application ProofShenzhen Immunofoco Biotechnology Co., Ltd.深圳易慕峰生物科技股份有限公司Develops CAR-T cell therapies for solid tumors, with lead candidates IMC002 (anti-CLDN18.2, second-most clinically advanced globally per the prospectus) and IMC001 (anti-EpCAM), plus an in vivo CAR-T platform, serving cancer patients in China and worldwide.
- 2026-08-12
Application ProofSuzhou Zelgen Biopharmaceuticals Co., Ltd.苏州泽璟生物制药股份有限公司Develops and commercializes innovative small-molecule and biologic therapies in China, focusing on oncology, autoimmune diseases, and hemostasis/hematology, with four commercialized drugs including Donafenib, a JAK inhibitor, recombinant human thrombin, and recombinant human thyrotropin.
- 2026-08-07
Application ProofSuzhou Genhouse Bio Co., Ltd.勤浩医药（苏州）股份有限公司Develops innovative oncology drugs targeting RAS signalling pathways and synthetic lethality, including a SHP2 inhibitor for solid tumours and KRAS-mutated cancers; pre-revenue clinical-stage biotech based in China.
- 2026-08-06
Application ProofBiopharmaceutical company developing bispecific ADCs, including iza-bren targeting EGFR and HER3. Licensed iza-bren to Bristol-Myers Squibb in a collaboration worth up to US$8.4 billion, retaining exclusive rights in Chinese Mainland while co-developing and commercializing in the US with BMS.
- 2026-07-24
Application ProofGuangzhou Novaken Pharm Co., Ltd.广州新济医药股份有限公司Clinical-stage pharmaceutical company developing modified new drugs using reformulation and drug-delivery technologies on approved APIs. Two core pipeline candidates: a microneedle patch for preoperative sedation and a nasal inhalation therapy for Parkinson's disease, in Phase II trials in China.
- 2026-07-24
Application ProofPrimeGenX Therapeutics Co., Ltd.北京普祺医药科技股份有限公司Develops small-molecule drugs for immune-inflammation diseases, delivered locally via gels, sprays, tablets and ophthalmic solutions. Lead candidate is a JAK1/2 inhibitor for atopic dermatitis and allergic rhinitis, alongside three innovative and five generic drug candidates in China.
- 2026-07-22
Application ProofProvides temperature-control supply chain services for the pharmaceutical and life science industry in China, covering clinical trials and commercial medical products, including packaging, labeling, storage, logistics and customs services, and manufactures temperature-control equipment. Largest such provider in China per Frost & Sullivan.
- 2026-07-17
Application ProofJPJ (TCM) Limited保济元和(TCM)有限公司Hong Kong-based proprietary Chinese medicine group selling branded PCM products such as Po Chai Pills and medicated oils, and operating Chinese medicine clinics; ranked first in the Hong Kong PCM market with 9.2% share by end-market sales in 2025, per Frost & Sullivan.
- 2026-07-16
Application ProofClinical-stage biotechnology company developing and manufacturing oncolytic immunotherapies and engineered exosome therapies for cancer treatment, including a Phase II HSV-1-based oncolytic candidate for bladder cancer and head and neck squamous cell carcinoma.
- 2026-07-09
Application ProofZiyond Pharmaceutical Co., Ltd.江苏知原药业股份有限公司Develops and commercializes topical dermatology pharmaceuticals and medical-grade skincare products in China, covering over 50 products across six therapeutic areas with an omnichannel network; per Frost & Sullivan, it has the broadest coverage of high-prevalence skin indications in China.
- 2026-07-08
Application ProofMing Yu Pharmaceutical Limited明宇制药有限公司Biotechnology company developing antibody-drug conjugates, a PD-1/VEGF bispecific antibody, and autoimmune drug candidates. Its pipeline of 11 candidates targets solid tumors including NSCLC and breast cancer, and thyroid eye disease, with programs in clinical and late-stage development.
- 2026-07-03
Application ProofJingze Biopharmaceutical (Hefei) Co., Ltd景泽生物医药(合肥)股份有限公司Biopharmaceutical company in China developing and manufacturing assisted reproductive drugs (rhFSH injections) and ophthalmic drugs, including one NMPA-approved product, one NDA under review, and a Phase 3 anti-VEGF candidate.
- 2026-06-30
Application ProofChengdu Olymvax Biopharmaceuticals Inc.成都欧林生物科技股份有限公司Develops, manufactures and commercializes vaccines in China, focusing on superbug and adult vaccines. Its commercialized products include an adsorbed tetanus vaccine, which ranked first in China's adsorbed tetanus vaccine market with ~98.8% share in 2025 (per CIC), alongside Hib and AC conjugate vaccines.
- 2026-06-30
Application ProofCOREE Company Limited科郦有限公司Korea-originated healthcare company operating mainly in China, providing medicine marketing, promotion and sales services through a nationwide distributor network, and developing, manufacturing and distributing maternity and supplement products. Ranked among China's top 10 medicine marketing, promotion and sales companies, with ~2.0% market share, per Frost & Sullivan.
- 2026-06-26
Application ProofFosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.复星安特金(成都)生物制药股份有限公司Develops, manufactures and commercializes prophylactic vaccines in China, including rabies and influenza vaccines, with a pipeline targeting pneumococcal and meningococcal diseases; operates R&D and manufacturing bases in Chengdu and Dalian, and ranked third in 2023 (per prospectus).
- 2026-06-25
Application ProofNeuroGen Pharma Limited神基制药有限公司Specialty pharmaceutical company focused on neurology, pain management and allergy in China, selling originator drugs such as Keppra, Vimpat, Zyrtec and AJOVY, with integrated R&D, manufacturing and commercialization and an innovative pipeline.
- 2026-06-25
Application ProofChina-based pharmaceutical company focused on kidney diseases, developing, manufacturing and commercializing drugs for kidney and hematologic, respiratory and dermatologic diseases in China.
- 2026-06-24
Application ProofEpimAb Biotherapeutics Inc.岸迈生物科技有限公司Clinical-stage biotechnology company developing bispecific antibody therapeutics, including T-cell engagers, for cancer and autoimmune diseases. Pipeline includes four clinical-stage candidates led by EMB-01 (EGFR/cMET) in Phase II for metastatic colorectal cancer, targeting markets including China.
- 2026-06-22
ProspectusDevelops and produces human antiserum biological products, including the largest human tetanus antitoxin supply in China, for passive immunization against tetanus, snakebite envenoming and rabies; also the largest exporter of human TAT in China per Frost & Sullivan.
- 2026-06-18
ProspectusClinical-stage biopharmaceutical company developing therapies for renal indications, including AP301, a phosphate binder for hyperphosphatemia in dialysis patients, in Phase III trials in China and the US; per CIC, it has the broadest renal indication coverage globally.
- 2026-06-18
Application ProofCSPC Innovation Pharmaceutical Co., Ltd.石药创新制药股份有限公司Produces chemically synthesized caffeine for use as a food additive in functional beverages, supplying beverage makers globally, and sells nutritional products under the Guoweikang brand through Chinese pharmacy chains. World's largest chemically synthesized caffeine producer by revenue and shipment from 2020 to 2025, per Frost & Sullivan.
- 2026-06-18
Application ProofGuangzhou Zhiyi Biotechnology Co., Ltd.广州知易生物科技股份有限公司Clinical-stage biopharmaceutical company developing live biotherapeutic products (LBPs) for gastrointestinal diseases, oncology, cancer therapy-related complications, metabolic, and autoimmune diseases, established in 2013.
- 2026-06-16
Application ProofShanghai Juncell Therapeutics Co., Ltd.上海君赛生物股份有限公司Develops cell therapies, notably tumor-infiltrating lymphocyte (TIL) therapies, for solid tumors. Its core candidate GC101 is the world's first TIL therapy not requiring high-intensity lymphodepletion chemotherapy or IL-2, per Frost & Sullivan, and operates in China.
- 2026-06-15
ProspectusBiotechnology company developing bi-/multi-specific peptide drugs for metabolic, cardiovascular and cerebrovascular diseases, with a Phase III core product for CKD-SHPT and three key clinical-stage candidates, all in-house developed, primarily in China.
- 2026-06-15
Application ProofLynk Pharmaceuticals Co., Ltd.凌科药业（浙江）股份有限公司Clinical-stage biotech developing small-molecule JAK and TYK2 inhibitors for autoimmune and inflammatory diseases, with two core drug candidates in clinical development and a pipeline of additional preclinical programs, based in China.
- 2026-06-15
Application ProofTRIAPEX LABORATORIES CO., LTD.江苏鼎泰药物研究(集团)股份有限公司Contract research organization providing nonclinical safety, efficacy and DMPK studies and integrated clinical trial services to pharmaceutical companies and research institutions worldwide, with focus on cardiometabolic, CNS, ophthalmology, autoimmune and oncology diseases. No. 1 CRO in China for nonclinical cardiometabolic studies in 2025, per Frost & Sullivan.
- 2026-06-12
ProspectusDevelops small-molecule drug candidates for autoimmune, metabolic and oncology diseases, including a TYK2 inhibitor, a GLP-1/GIP agent and a KRAS G12C inhibitor, using an integrated in silico and experimental discovery and development platform; pipeline-focused biotech in China.
- 2026-06-12
Application ProofYantai Lannacheng Biotechnology Co., Ltd.烟台蓝纳成生物技术股份有限公司Clinical-stage biotechnology company developing diagnostic and therapeutic radiopharmaceuticals for oncology, with a pipeline of 13 candidates including a registrational-stage PET imaging agent for PSMA-positive prostate cancer, based in China.
- 2026-06-08
Application ProofHangzhou Highlightll Pharmaceutical Co., Ltd.杭州高光制药股份有限公司Clinical-stage biotechnology company developing small-molecule therapeutics for autoimmune/inflammatory and neurodegenerative diseases, including TYK2/JAK1 inhibitors with Phase III trials in China for chronic spontaneous urticaria and rheumatoid arthritis.
- 2026-06-08
Application ProofGANZHOU HEMAY PHARMACEUTICAL CO., LTD.赣州和美药业股份有限公司Discovers and develops small-molecule drug candidates for autoimmune diseases and oncology, with a pipeline of seven candidates including one approved drug, targeting indications with unmet medical needs.
- 2026-06-01
Application ProofIntellective Biologics (Suzhou) Co., Ltd.智享生物（苏州）股份有限公司Provides biologics CDMO services in China, covering process development through commercial manufacturing of biologics, including therapeutic antibodies. Ranked second among China biologics CDMOs by number of commercial products and third in therapeutic antibodies by revenue in 2025, per Frost & Sullivan.
- 2026-05-29
Application ProofGenuine Biotech Limited真实生物科技有限公司Develops, manufactures and commercializes novel drugs for viral infections, oncology and cardio-cerebrovascular diseases in China, with a portfolio of seven candidates centered on azvudine for HIV and COVID-19, plus CL-197 and dosimertinib.
- 2026-05-28
ProspectusClinical-stage biopharmaceutical company based in Shanghai and Changshu, China, discovering and developing biologic antibodies for allergic and autoimmune diseases; core product LP-003, an anti-IgE antibody for seasonal allergic rhinitis, is in Phase III trials in China.
- 2026-05-28
Application ProofLupeng Pharmaceutical Ltd.麓鹏制药有限公司Develops LP-168, a dual-mechanism (covalent and non-covalent) BTK inhibitor for blood cancers including DLBCL, MCL and CLL/SLL, at NDA stage with clinical trials in the US and China.
- 2026-05-27
Application ProofClinical-stage biopharmaceutical company developing cancer therapies targeting the tumor microenvironment, with a pipeline of six lead clinical and preclinical immuno-oncology assets including OX40 (ES102) and CD39/TGF-β (ES014), and also pursuing autoimmune disease treatments.
- 2026-05-22
Application ProofSINOCELLTECH GROUP LIMITED北京神州细胞生物技术集团股份公司Develops, manufactures and commercializes therapeutic antibodies, recombinant proteins and vaccines in China, with five commercialized products including rhFVIII Anjiayin, which ranked first in sales value among comparable products in China since 2023 per CIC, with about 35.5% market share in 2024.
- 2026-05-18
Application ProofBRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.博瑞生物医药（苏州）股份有限公司Develops and manufactures active pharmaceutical ingredients, intermediates, generics and some innovative drugs, plus R&D and manufacturing services for pharmaceutical companies, selling to over 40 countries. Ranked among top three global echinocandin API/intermediate suppliers in 2025, per CIC.
- 2026-05-18
Application ProofZhejiang Shimai Pharmaceutical Co., Ltd.浙江时迈药业股份有限公司Clinical-stage biotech developing T-cell engager (TCE) therapies, including masked TCEs for solid tumors, targeting oncology markets in China and globally.
- 2026-05-14
ProspectusNear-commercial stage biotechnology company developing therapies for bacterial infections and gut bacterial metabolism-related diseases, targeting antimicrobial resistance, using its multi-targeting conjugate molecule technology.
- 2026-05-06
Application ProofKexing Biopharm Co., Ltd.科兴生物制药股份有限公司Develops, manufactures and commercializes biologic drugs, including recombinant proteins, antibodies and targeted-delivery therapies, focusing on oncology and autoimmune diseases, with commercialized products and pipeline candidates sold to patients worldwide.
- 2026-05-05
ProspectusDevelops AI-driven nanomaterial delivery technologies, including a proprietary lipid library and AI platforms, to design lipid nanoparticles for drug delivery, serving pharmaceutical development of innovative medicines, with expansion into longevity and animal health.
- 2026-05-05
ProspectusDevelops synthetic lethality-based precision anti-cancer therapies, with commercialized senaparib for first-line maintenance therapy in ovarian cancer in China; pipeline includes ADCs and degraders, with partnerships with global biotech and China pharmaceutical companies.
- 2026-04-30
Application ProofSichuan Neautus Traditional Chinese Medicine Co., Ltd.四川新荷花中药饮片股份有限公司Produces and sells TCM decoction-ready products in China, serving hospitals, medical institutions, pharmacies, pharmaceutical companies and retail consumers, also offering wellness products and health management services. Ranks second in China by TCM decoction-ready product revenue in 2024 with 0.4% market share.
- 2026-04-29
Application ProofEccogene Inc.诚益生物开曼有限公司Clinical-stage biotechnology company developing small-molecule drug candidates for cardiometabolic diseases, including MASH and obesity, with a pipeline of three clinical-stage and three preclinical programs; operates in China and the United States, listed in Hong Kong.
- 2026-04-24
Application ProofBeijing QL Biopharmaceutical Co., Ltd.北京质肽生物医药科技股份有限公司Biopharmaceutical company developing therapies for obesity and metabolic disorders, including a monthly GLP-1 receptor agonist injection (zovaglutide) in Phase III trials in China, with integrated peptide discovery, clinical development, and GMP manufacturing capabilities.
- 2026-04-21
Application ProofLate-stage biotechnology company developing small-molecule oncology drugs, focusing on a FAK inhibitor, ifebemtinib, in registrational studies in China for tumor treatment resistance.
- 2026-04-20
ProspectusDevelops and commercializes innovative drugs in China, focused on oncology, immunology, ophthalmology and orthopedics, with four commercialized products and a pipeline including the Nectin-4 targeting ADC 9MW2821 in Phase III trials.
- 2026-04-02
Application ProofShanghai Huilun Pharmaceutical Co., Ltd.上海汇伦医药股份有限公司Pharmaceutical company in China with integrated R&D, manufacturing and commercialization, selling over ten marketed drugs including sivelestat sodium and levofolinic acid products, with a pipeline of Category I innovative drugs in immunology, pain management and oncology.
- 2026-04-02
Application ProofBinhui Biopharmaceutical Co., Ltd.武汉滨会生物科技股份有限公司China-based biotechnology company developing oncolytic virus cancer immunotherapies, including core clinical-stage candidate BS001 (OH2 Injection), an HSV-2-based oncolytic virus for advanced solid tumors, plus additional clinical and preclinical pipeline candidates.
- 2026-03-31
Application ProofDevelops siRNA (small interfering RNA) therapeutics targeting chronic diseases, with key franchises in coagulation disorders, cardiometabolic diseases and obesity, focused on preventive long-term disease management.
- 2026-03-23
Application ProofHangzhou Sciwind Biosciences Co., Ltd.杭州先为达生物科技股份有限公司Biopharmaceutical company developing weight management therapeutics for obesity and related diseases, including GLP-1 injectable ecnoglutide for overweight/obesity, T2DM, MASH and OSA, with one core product and seven pipeline products; operations in China.
- 2026-03-20
Application ProofAtom Therapeutics Co., Ltd.杭州新元素药业股份有限公司Develops ABP-671, a next-generation URAT1 inhibitor for gout, currently in Phase 2b/3 clinical trials in the US and China, with clinical data from over 900 patients across the US, China, Australia and other regions.
- 2026-03-17
Application ProofShanghai Ark Biopharmaceutical Co., Ltd.上海爱科百发生物医药技术股份有限公司Biopharmaceutical company developing therapeutics for respiratory and pediatric diseases in China, with a pipeline including an RSV antiviral (ziresovir) at NDA stage, an RSV-prevention mAb, an IPF drug, and an approved ADHD drug.
- 2026-02-27
Application ProofBeijing Wehand-Bio Pharmaceutical Co., Ltd.北京五和博澳药业股份有限公司Develops and commercializes natural medicine-based therapies and drug delivery systems in China, with one marketed drug for type 2 diabetes and a pipeline targeting PCOS, obesity, and breast cancer.
- 2025-12-31
ProspectusDevelops siRNA-based oligonucleotide therapeutics, with a pipeline of seven clinical-stage drug candidates across cardiovascular, metabolic, renal and liver diseases, including a lead FXI-targeting siRNA for thrombotic diseases; operates in China.
- 2025-12-18
ProspectusOperates an AI-driven drug discovery and development company using its proprietary generative AI platform Pharma.AI to discover drug candidates, deriving revenue primarily from out-licensing and collaboration arrangements with international pharmaceutical companies globally.
- 2025-12-15
ProspectusClinical-stage biotech developing an oncology drug pipeline, including HX009, a bifunctional anti-PD-1 SIRP fusion protein, plus kinase inhibitors and preclinical antibody candidates (ADCs, bispecifics, mAbs) for cancer and autoimmune diseases in China and Australia.
- 2025-12-12
ProspectusChina-based biopharmaceutical company developing protein drugs for wound healing, focusing on PDGF therapies for burns and diabetic foot ulcers. Its pipeline includes two core products in clinical trials and eight other candidates.
- 2025-12-02
ProspectusBiotechnology company founded in 2019 developing engineered enzymes for large-volume subcutaneous drug delivery, IgG-mediated autoimmune diseases, assisted reproduction, and recombinant biologic products in China. Core pipeline includes recombinant human hyaluronidase KJ017 and IgG-degrading enzyme KJ103.
- 2025-10-28
ProspectusBiopharmaceutical company discovering, developing and commercializing small-molecule drugs focused on neuropsychiatry and reproductive health, with core product candidates LV232 for major depressive disorder and TPN171 for erectile dysfunction, plus four clinical-stage and three pre-clinical candidates.
- 2025-10-09
ProspectusCommercial-stage pharmaceutical company in China integrating R&D, production and sales of generic drugs for digestive, cardiovascular, endocrine, nervous system and inflammatory diseases, with a pipeline of in-house innovative candidates including oncology and retinal disease therapies.
- 2025-10-06
ProspectusDevelops innovative pharmaceutical drugs in China, with a pipeline of over ten drug assets targeting digestive diseases, oncology and NASH, including three NDA-approved products; majority-owned by Sihuan Pharm.
- 2025-09-26
ProspectusDevelops, manufactures and commercializes inhalation drugs for respiratory diseases in China, with products approved by NMPA and FDA. Main product CF017, a budesonide inhalation suspension, accounted for about 16% of China's budesonide inhalation market by sales volume in 2024, per F&S.
- 2025-09-11
ProspectusDevelops oncology and autoimmune drug candidates, including KRAS inhibitors, for solid tumor treatment in China and globally. Its lead product fulzerasib was China's first and the world's third approved KRAS G12C inhibitor, with a pipeline of eight candidates.
- 2025-08-07
ProspectusDevelops drug candidates for diabetes and metabolic diseases in China, including Efsubaglutide Alfa, approved in January 2025 for type 2 diabetes and in development for obesity, overweight, and MASH, with five pre-clinical candidates.
- 2025-07-31
ProspectusDevelops, manufactures and commercializes vaccines in China, including a quadrivalent subunit influenza vaccine approved in 2023 and a freeze-dried human rabies vaccine candidate, with 11 other vaccine candidates in the pipeline.
- 2025-07-17
ProspectusClinical-stage biotechnology company developing bispecific antibodies and other therapies for oncology, autoimmune, and other severe diseases. Its core product, LBL-024, a PD-L1/4-1BB dual-targeting bispecific antibody, is in registrational trials, with 13 other drug candidates in the pipeline.
- 2025-06-24
ProspectusClinical-stage biotechnology company developing novel ophthalmic therapies for eye diseases, with in-house drug discovery and development targeting global unmet needs, particularly conditions like pterygium and vascularised pinguecula lacking treatment options.
- 2025-06-20
ProspectusProvides peptide-focused CRDMO services covering discovery, preclinical and clinical development, and commercial-stage production for biopharmaceutical clients. Ranked third largest peptide-focused CRDMO worldwide with 1.5% market share in 2023, per Frost & Sullivan.
- 2025-06-13
ProspectusClinical-stage biopharmaceutical company developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Its core product, Tinengotinib, a multi-targeted kinase inhibitor, is in registrational trials for cholangiocarcinoma in China and the US, with a pipeline of five clinical-stage candidates.
- 2025-05-19
ProspectusDevelops peptide and small molecule drugs for chronic and metabolic diseases, including type 2 diabetes, obesity, NASH and OIC, with a lead near-commercialized GLP-1 receptor agonist (PB-119). Operates in China.
- 2025-05-15
ProspectusDevelops, manufactures and commercializes innovative pharmaceutical drugs, focusing on new molecular entity therapies in oncology and other areas with unmet medical needs, in China and globally. Ranked first among Chinese pharma companies in NME drug revenue in 2023 per Frost & Sullivan.
- 2025-04-07
ProspectusDevelops antibody-drug conjugate (ADC) therapeutics for cancers and autoimmune diseases. Lead candidates include a HER2 ADC and a B7-H3 ADC, plus additional clinical-stage and preclinical ADCs. Incorporated in 2019, with candidates among the most clinically advanced globally per Frost & Sullivan.
- 2025-03-13
ProspectusBiopharmaceutical company developing treatments for endocrinology diseases in Greater China, with a weekly long-acting growth hormone therapy for pediatric growth hormone deficiency and pipeline candidates for achondroplasia and chronic hypoparathyroidism, in-licensed from Ascendis Pharma.
- 2024-11-20
ProspectusBiopharmaceutical company in Zhejiang, China engaged in R&D, manufacturing and commercialization of biopharmaceutical products and medical devices, focused on orthopedics, metabolic diseases, oncology and hematology; has eight marketed products including China's first rhBMP-2 bone repair material.
- 2024-10-23
ProspectusDevelops oncology drugs using synthetic biology and microbial metabolite technology platforms. Its commercialized product, Utidelone Injection, approved by the NMPA in 2021, treats relapsed or metastatic breast cancer, with 19 pipeline candidates covering various solid tumors in China.
- 2024-09-27
ProspectusProvides cloud-based software and digital services for pharmaceutical and medical device companies in China, supporting clinical trial management, patient recruitment, medical image reading, SMO resource execution, and pharmacovigilance across drug R&D and commercialization workflows.
- 2024-08-12
ProspectusClinical-stage biopharmaceutical company developing targeted oncology therapies in China, with 11 drug candidates including TY-9591 in Phase II/III trials for EGFR-mutated non-small cell lung cancer.
- 2024-06-04
ProspectusQuantumPharm Inc.02228.HKProvides drug and material science R&D solutions and services using quantum physics-based first-principles calculation, AI, cloud computing, and robotic automation, serving pharmaceutical and material science companies globally and domestically. Recognized as a global leader in computational solid-state R&D services per the prospectus.
- 2024-05-16
ProspectusClinical-stage biopharmaceutical company discovering and developing biologics, including an ADCC-enhanced monoclonal antibody and immunocytokines, for cancers and autoimmune diseases, with three core products in Phase I/II trials and nine additional pipeline candidates.
- 2024-03-12
ProspectusClinical-stage biotech developing biologic therapies for autoimmune and allergic diseases in China. Lead candidates include QX002N, an IL-17A inhibitor in Phase III for ankylosing spondylitis, and QX005N, an IL-4R monoclonal antibody in Phase II trials, with nine pipeline candidates.
- 2023-12-14
ProspectusDevelops multifunctional, multi-targeted therapies for metabolic and digestive diseases, with a pipeline led by HTD1801, a gut-liver anti-inflammatory metabolic modulator; operates as a clinical-stage biopharmaceutical company in China.
- 2023-11-07
ProspectusProvides CRDMO services for antibody-drug conjugates (ADCs) and other bioconjugates, covering discovery, research, development and manufacturing for global biopharmaceutical companies. Ranked the second largest global ADC/bioconjugate CRDMO by 2022 revenue, per Frost & Sullivan.
- 2023-09-13
ProspectusDevelops bispecific antibody therapies for cancer-associated complications, cancer, and age-related ophthalmologic diseases, with a pipeline of seven clinical-stage candidates led by M701 in Phase II trials for malignant ascites and malignant pleural effusion, in China.
- 2023-08-24
ProspectusClinical-stage biotechnology company in the PRC developing immuno-oncology therapies, with a pipeline of 14 drug candidates centered on CD47-targeted innate-immunity assets, including CD47-based bispecific molecules, for cancer treatment.
- 2023-06-29
ProspectusBiopharmaceutical company developing, manufacturing and commercializing novel drugs in oncology and immunology, with a focus on ADC therapeutics. Its core products include a phase 3 TROP2 ADC and an NDA-stage HER2 ADC for advanced solid tumors, plus 12 clinical-stage assets.
- 2023-06-16
ProspectusClinical-stage biotechnology company developing oncology drug candidates, including an AKT inhibitor and an androgen synthesis inhibitor for ovarian, prostate and breast cancers, with two core products in-licensed from Novartis and six ongoing clinical trials.
- 2023-05-31
ProspectusR&D-driven dermatology-focused biopharmaceutical company developing treatments for localized adipose accumulation, scalp and skin diseases, and topical anesthesia, with one core recombinant collagenase candidate and eight pipeline products; also distributes two commercialized products from overseas partners, primarily in China.
- 2023-04-25
ProspectusDevelops recombinant human vaccines and therapeutic biologics for infectious diseases, cancer, and autoimmune diseases, with three clinical-stage and four pre-clinical product candidates, primarily in China with target markets including the U.S. and other jurisdictions.